Triple Negative Breast Cancer (TNBC) is believed to be an immunogenic tumor, therefore; immunotherapy has arisen to be a promising approach for TNBC treatment. Immune escape can be caused by the inactivation of natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). NKs and CTLs express an array of activating receptors on their surface that bind to unique activating ligands exclusively present on cancer cells such as MICA, MICB and CD155. Unfortunately, the expression of these immune ligands is decreased by malignant cells through their shedding down. Interestingly, non-coding RNAs...